HUMAHumacyte, Inc.

Nasdaq humacyte.com


$ 7.00 $ -0.21 (-2.92 %)    

Tuesday, 11-Jun-2024 15:59:50 EDT
QQQ $ 468.10 $ 3.19 (0.69 %)
DIA $ 388.08 $ -1.32 (-0.34 %)
SPY $ 537.01 $ 1.29 (0.24 %)
TLT $ 91.83 $ 0.94 (1.03 %)
GLD $ 214.15 $ 0.61 (0.29 %)
$ 6.99
$ 7.03
$ 6.99 x 100
$ 7.00 x 100
$ 6.74 - $ 7.10
$ 1.96 - $ 9.97
1,438,751
na
756.64M
$ 1.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 03-28-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-24-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-13-2022 03-31-2022 10-Q
10 03-29-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 02-16-2021 12-31-2020 10-K
15 11-13-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 benchmark-reiterates-buy-on-humacyte-maintains-15-price-target

Benchmark analyst Bruce Jackson reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $15 price target.

 benchmark-reiterates-buy-on-humacyte-maintains-15-price-target

Benchmark analyst Bruce Jackson reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $15 price target.

 humacyte-q1-eps-029-misses-023-estimate-exits-quarter-with-cash--equivalents-worth-1155m

Humacyte (NASDAQ:HUMA) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.22) by...

 tommy-tuberville-trades-raise-eyebrows-again-senator-sells-put-options-buys-small-biotech-linked-to-ukraine-russia-war

Tommy Tuberville is one of the most active traders as a member of Congress. Here's a look at what he recently bought and sold.

 cantor-fitzgerald-reiterates-overweight-on-humacyte-maintains-7-price-target

Cantor Fitzgerald analyst Kristen Kluska reiterates Humacyte (NASDAQ:HUMA) with a Overweight and maintains $7 price target.

 piper-sandler-maintains-neutral-on-humacyte-maintains-4-price-target

Piper Sandler analyst Allison Bratzel maintains Humacyte (NASDAQ:HUMA) with a Neutral and maintains $4 price target.

 benchmark-reiterates-buy-on-humacyte-maintains-15-price-target

Benchmark analyst Bruce Jackson reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $15 price target.

 earnings-scheduled-for-march-22-2024

Companies Reporting Before The Bell • Agile Therapeutics (NASDAQ:AGRX) is likely to report quarterly loss at $0.54 per share o...

 investor-optimism-improves-slightly-dow-jumps-over-250-points

The CNN Money Fear and Greed index showed a slight increase in the overall market sentiment on Thursday.

 earnings-preview-humacyte
Earnings Preview: Humacyte
03/21/2024 14:00:24

 senator-tommy-tubervilles-latest-2-stock-trades-attract-the-wrong-kind-of-attention-should-this-be-allowed

Stock trades made by Senator Tommy Tuberville are drawing scrutiny on social media with potential conflicts of interest.